Metal Complexes in Medicine: Platinum Drugs, Imaging Agents and Chelation Therapy
CSIR NET chemistry: cisplatin mechanism, carboplatin and oxaliplatin, Gd MRI agents, technetium-99m, chelation therapy, gold, lithium and bismuth drugs.
- 15 min
On this page · 15 sections
Prerequisites
- Reaction Mechanisms: Substitution and Electron Transfer: square planar substitution, the trans effect and the synthesis of cisplatin.
- HSAB Concept: the basis of every chelating antidote.
- Inner Transition Elements: Electronic Structure, Ground Terms and Magnetic Properties: why Gd³⁺ (\( f^7 \)) is the MRI ion of choice.
- Porphyrins and Oxygen Transport: heme biosynthesis, the target of lead.
The Hook: A Bacterium That Stopped Dividing
Essential, Toxic and Therapeutic
Every element shows a dose–response: deficiency at low intake, an optimal range, and toxicity at high intake (a Bertrand diagram). Essential metals (Fe, Zn, Cu, Mn, Co, Mo) and non-essential ones (Pt, Au, Gd, Tc, Li, Bi) are both used in medicine.
| Use | Examples |
|---|---|
| Anticancer | cisplatin, carboplatin, oxaliplatin (Pt); arsenic trioxide (As) |
| Imaging | Gd(III) chelates (MRI), ⁹⁹ᵐTc complexes (SPECT), BaSO₄ (X-ray) |
| Antidotes / chelation | BAL, DMSA, CaNa₂EDTA, D-penicillamine, desferrioxamine, Prussian blue |
| Other drugs | lithium carbonate, auranofin (Au), bismuth salts, sodium nitroprusside (Fe), silver sulfadiazine, antimony(V) drugs |
| Supplements | iron salts, zinc, vitamin B₁₂ (Co) |
Platinum Anticancer Drugs
Cisplatin: structure and synthesis
cis-Diamminedichloridoplatinum(II), cis-[PtCl₂(NH₃)₂]: square planar Pt(II), \( d^8 \), diamagnetic, neutral.
It is made from K₂[PtCl₄] using the trans effect (Cl⁻ > NH₃): the first NH₃ replaces any Cl⁻; the second replaces a Cl⁻ trans to Cl⁻, giving the cis isomer. (A cleaner route goes through [PtI₄]²⁻, because I⁻ has a still larger trans effect, then exchanges iodide for chloride.) Transplatin is made from [Pt(NH₃)₄]²⁺ and Cl⁻.
Mechanism of action
graph TD
A[Blood: high chloride, cisplatin stays as PtCl2 NH3 2] --> B[Enters cell: passive diffusion and transporters such as CTR1]
B --> C[Cell: low chloride, aquation to PtCl NH3 2 H2O +]
C --> D[Binds N7 of guanine in DNA]
D --> E[Second aquation and closure: 1,2-intrastrand GpG crosslink]
E --> F[DNA bent and unwound; HMG proteins bind; replication and transcription blocked]
F --> G[Apoptosis]- Chloride gradient. Plasma chloride is high (about 100 mM), so cisplatin stays largely intact in the blood. Inside cells chloride is much lower (a few to a few tens of mM), and the complex aquates: Cl⁻ is replaced by water, giving cis-[PtCl(NH₃)₂(H₂O)]⁺, the reactive species. Aquation is the rate-determining activation step.
- DNA binding. Pt binds the N7 of guanine (exposed in the major groove, the most nucleophilic site). The main adduct is the 1,2-intrastrand d(GpG) crosslink (the majority of adducts), followed by 1,2-d(ApG); 1,3-intrastrand and interstrand crosslinks are minor.
- Structural damage. The crosslink bends the DNA towards the major groove and unwinds it. HMG-domain proteins bind the bent DNA and shield it from repair; replication and transcription stall, and the cell undergoes apoptosis.
Why transplatin is inactive: its two leaving groups are 180° apart, so it cannot form the 1,2-intrastrand crosslink between adjacent guanines. It also reacts faster with other nucleophiles (because the trans ligand labilises), and its adducts are repaired more readily.
Toxicity and resistance. Pt(II) is soft and binds sulfur: glutathione and metallothionein deactivate it, and kidney damage (nephrotoxicity; reduced with hydration) and hearing loss are dose-limiting. Resistance comes from lower uptake, more thiol scavenging and increased nucleotide excision repair.
Second- and third-generation drugs
| Drug | Leaving group | Carrier (non-leaving) ligands | Key difference |
|---|---|---|---|
| Cisplatin | 2 Cl⁻ | 2 NH₃ | most potent, most nephrotoxic |
| Carboplatin | cyclobutane-1,1-dicarboxylate (chelating) | 2 NH₃ | slower activation, less nephrotoxic; bone-marrow toxicity limits dose; same DNA adducts |
| Oxaliplatin | oxalate (chelating) | (1R,2R)-1,2-diaminocyclohexane (DACH) | bulky DACH adducts are not recognised by the same repair proteins; active in some cisplatin-resistant tumours (colorectal) |
Structure–activity rules (classic, for Pt(II) ammines): neutral complexes; cis geometry; two leaving groups of moderate lability (too labile → reacts with everything before reaching DNA; too inert → never activates); amine carrier ligands with at least one N–H (for hydrogen bonding to DNA).
Pt(IV) prodrugs (octahedral, \( d^6 \), kinetically inert) such as satraplatin carry two extra axial ligands and are reduced to the active Pt(II) inside cells.
Imaging Agents
Gadolinium MRI contrast agents
MRI images water protons. A contrast agent shortens the relaxation time T₁ of nearby water, making those tissues brighter in T₁-weighted images.
Why Gd³⁺: \( 4f^7 \), S = 7/2, seven unpaired electrons (the maximum for an f-block ion), and an \( ^8S \) ground state with no orbital angular momentum, so its electron spin relaxation is slow. That combination makes it the most efficient relaxer of water protons.
Why chelates: free Gd³⁺ is toxic (similar size to Ca²⁺; it blocks calcium channels and precipitates as phosphate). It is given as a very stable, nine-coordinate complex with one water left on the metal:
| Agent | Ligand | Type |
|---|---|---|
| Gadopentetate, [Gd(DTPA)(H₂O)]²⁻ | DTPA (octadentate) | linear |
| Gadoterate, [Gd(DOTA)(H₂O)]⁻ | DOTA (octadentate) | macrocyclic |
Relaxivity (r₁, in mM⁻¹ s⁻¹) depends on: the number of inner-sphere waters (q), their exchange rate with bulk water (must be fast), and the rotational correlation time (slower tumbling, for example when bound to a protein, raises relaxivity). These are combined in the Solomon–Bloembergen–Morgan theory. The observed rate is:
$$\boxed{\frac{1}{T_{1,\text{obs}}} = \frac{1}{T_{1,0}} + r_1[\text{Gd}]}$$Macrocyclic agents are kinetically more inert than linear ones (Gd³⁺ release is slower). Release of Gd³⁺ from less stable agents in patients with poor kidney function has been linked to nephrogenic systemic fibrosis, which is why kinetic inertness, not just thermodynamic stability, matters here.
Technetium-99m
⁹⁹ᵐTc is the workhorse of nuclear medicine (SPECT): an almost pure γ emitter (isomeric transition) of about 140 keV with a 6-hour half-life, ideal for imaging with little radiation dose.
- Generator: ⁹⁹Mo (half-life about 66 h), adsorbed on alumina as molybdate, decays to ⁹⁹ᵐTc; saline elutes pertechnetate, TcO₄⁻ (Tc(VII)), while molybdate stays on the column.
- Kits: a vial contains a ligand and a reductant (usually Sn(II)). Adding TcO₄⁻ reduces Tc to a lower oxidation state, which the ligand captures.
- Examples: [Tc(MIBI)₆]⁺ (sestamibi, Tc(I), a lipophilic cation for heart imaging, six isonitrile ligands, low-spin \( d^6 \)); Tc–diphosphonate complexes for bone scans; neutral lipophilic Tc(V) complexes for brain perfusion.
Other radiometals: ²⁰¹Tl⁺ (heart, K⁺ mimic), ⁶⁷Ga/⁶⁸Ga and ¹¹¹In (bound to chelators such as DOTA on targeting peptides), ¹⁷⁷Lu (therapy), ²²³Ra (bone metastases, Ca²⁺ mimic).
Chelation Therapy
A good chelating antidote must: bind the target metal selectively (HSAB match) and strongly at physiological pH; not strip essential metals (Ca²⁺, Zn²⁺); reach the metal (lipophilicity, oral or injectable); and give a complex that is excreted (usually via the kidneys).
| Poisoning / disorder | Agent | Donor atoms | Logic |
|---|---|---|---|
| As, Hg, (Pb) | BAL (British anti-Lewisite, 2,3-dimercaptopropan-1-ol) | S, S (O) | soft thiols for soft metals; developed against the arsenical war gas lewisite |
| Pb, Hg, As | DMSA (succimer), DMPS | S, S | water-soluble, orally active dithiol analogues of BAL |
| Pb | CaNa₂EDTA | N₂O₄ | Pb²⁺ displaces Ca²⁺ (much larger log K); the calcium salt is used so blood Ca²⁺ is not stripped |
| Cu (Wilson’s disease) | D-penicillamine, trientine; also zinc salts (block absorption) and tetrathiomolybdate | S, N, O | removes accumulated copper |
| Fe overload (thalassaemia, repeated transfusions) | desferrioxamine (injectable), deferiprone, deferasirox (oral) | mainly O (hydroxamate, hydroxypyridinone, phenolate; deferasirox also uses one triazole N) | hard O donors for hard Fe(III) |
| Tl⁺, ¹³⁷Cs⁺ | Prussian blue (oral) | — | ion exchange in the gut; not a chelator |
Desferrioxamine B is a bacterial siderophore: a linear molecule with three hydroxamate groups that wraps Fe(III) in a hexadentate, octahedral O₆ environment with an extremely high stability constant (around 10³⁰). Deferiprone is bidentate (3 : 1 complex), deferasirox tridentate (2 : 1).
Other Metallodrugs
| Drug | Metal | Use and chemistry |
|---|---|---|
| Lithium carbonate | Li⁺ | bipolar disorder; Li⁺ mimics Mg²⁺ (diagonal relationship) and inhibits Mg-dependent enzymes such as inositol monophosphatase and GSK-3; narrow therapeutic window, blood levels are monitored |
| Auranofin | Au(I) | rheumatoid arthritis, oral; linear Au(I) with a thioglucose and triethylphosphine; Au(I) is soft and targets thiol/selenol enzymes (thioredoxin reductase) |
| Sodium aurothiomalate | Au(I) | injectable antiarthritic |
| Bismuth subsalicylate, colloidal bismuth subcitrate | Bi(III) | peptic ulcers, Helicobacter pylori, diarrhoea |
| Sodium nitroprusside, Na₂[Fe(CN)₅(NO)] | Fe(II), NO⁺ | releases NO, a vasodilator, for hypertensive emergencies; also releases cyanide |
| Silver sulfadiazine | Ag(I) | antibacterial for burns |
| Sodium stibogluconate | Sb(V) | leishmaniasis |
| Arsenic trioxide | As(III) | acute promyelocytic leukaemia |
| Ru(III) complexes (NAMI-A, KP1019) | Ru | anticancer candidates tested in clinical trials; activated by reduction to Ru(II) in hypoxic tumours |
| Vanadium complexes (e.g. bis(maltolato)oxovanadium(IV)) | V(IV) | insulin-mimetic research compounds; vanadate mimics phosphate |
Toxic Metals in Brief
| Metal | Target / mechanism | Notes |
|---|---|---|
| Pb²⁺ | binds thiols; inhibits ALA dehydratase (a Zn enzyme) and ferrochelatase | anaemia; raised ALA and zinc protoporphyrin |
| Hg (especially CH₃Hg⁺) | very soft, binds thiols; methylmercury crosses membranes and the blood–brain barrier | Minamata disease |
| Cd²⁺ | replaces Zn²⁺ in enzymes; induces metallothionein; kidney and bone damage | itai-itai disease |
| As | As(III) binds dithiols (e.g. lipoic acid); arsenate mimics phosphate (uncouples ATP synthesis) | BAL, DMSA, DMPS |
Memory Tricks
Don’t Confuse
| This | vs | That |
|---|---|---|
| Cisplatin: cis, active, 1,2-intrastrand GpG | transplatin: trans, inactive, cannot make 1,2-crosslink | |
| Carboplatin: dicarboxylate leaving group, NH₃ carriers | oxaliplatin: oxalate leaving group, DACH carrier | |
| Leaving group (Cl⁻, oxalate): lost on activation | carrier ligand (NH₃, DACH): stays on Pt in the DNA adduct | |
| Gd chelate: T₁ (positive) agent | iron oxide nanoparticles: T₂ (negative) agents | |
| Thermodynamic stability of Gd agent (log K) | kinetic inertness (rate of Gd³⁺ release) | |
| BAL / DMSA: S donors for soft metals | desferrioxamine: O donors for Fe(III) | |
| ⁹⁹ᵐTc: diagnostic γ emitter | ¹⁷⁷Lu, ²²³Ra: therapeutic (particle emitters) |
Common Mistakes
Practice
All questions below are original practice questions written for this page. They are not from any CSIR NET paper.
Level 1: Foundation
- Which atom of guanine does platinum bind in cisplatin–DNA adducts?
- What is the oxidation state of technetium in pertechnetate?
- Which chelator is used to treat iron overload by injection?
Answers
- N7.
- +7 (TcO₄⁻).
- Desferrioxamine.
Level 2: Part B Style
Practice Q1. Transplatin is inactive as an anticancer drug mainly because:
(a) it cannot enter cells (b) it cannot form 1,2-intrastrand crosslinks between adjacent guanines (c) it does not aquate (d) it is paramagnetic
Answer: (b)
The two labile positions are 180° apart. It aquates and enters cells, and like cisplatin it is \( d^8 \) square planar and diamagnetic.
Practice Q2. Gd³⁺ is preferred over other lanthanide ions for MRI contrast agents because it has:
(a) the largest orbital angular momentum (b) seven unpaired electrons and slow electron spin relaxation (c) the smallest ionic radius (d) intense f–f absorption
Answer: (b)
\( f^7 \), S = 7/2, L = 0 (\( ^8S \)): maximum spin and slow electronic relaxation, the two properties that make proton relaxation efficient.
Practice Q3. The most suitable antidote for acute arsenic poisoning is:
(a) desferrioxamine (b) BAL (dimercaprol) (c) Prussian blue (d) lithium carbonate
Answer: (b)
As(III) is soft and binds dithiols; BAL’s two thiols form a stable five-membered chelate ring. Desferrioxamine is for Fe(III), Prussian blue for Tl⁺/Cs⁺.
Practice Q4. A dose of ⁹⁹ᵐTc (half-life 6.0 h) has an activity of 800 MBq at 8 a.m. Its activity at 2 p.m. and at 8 a.m. the next day are:
(a) 400 and 50 MBq (b) 600 and 100 MBq (c) 400 and 100 MBq (d) 200 and 25 MBq
Answer: (a)
6 h = one half-life: 400 MBq. 24 h = four half-lives: 800/2⁴ = 50 MBq.
Level 3: Part C Style
Practice Q5. In a ⁹⁹Mo/⁹⁹ᵐTc generator, the parent has a half-life of 66 h and the daughter 6.01 h. After an elution removes all ⁹⁹ᵐTc, when does the daughter activity reach its maximum? Use \( t_{max} = \dfrac{\ln(\lambda_d/\lambda_p)}{\lambda_d - \lambda_p} \).
Answer
\( \lambda_p = 0.693/66 = 0.01050 \) h⁻¹; \( \lambda_d = 0.693/6.01 = 0.1153 \) h⁻¹.
\( \ln(\lambda_d/\lambda_p) = \ln(10.98) = 2.396 \); \( \lambda_d - \lambda_p = 0.1048 \) h⁻¹.
\( t_{max} \approx 2.396/0.1048 \approx \) 22.9 h. This is why generators are conveniently eluted about once a day.
Practice Q6. Tissue water has \( T_{1,0} \) = 2.0 s. A Gd agent with relaxivity r₁ = 4.0 mM⁻¹ s⁻¹ (practice value) reaches 0.50 mM in the tissue. Calculate the new T₁. If binding to a protein raised r₁ to 20 mM⁻¹ s⁻¹, what concentration would give the same T₁?
Answer
\( 1/T_1 = 1/2.0 + (4.0)(0.50) = 0.50 + 2.0 = 2.5 \) s⁻¹, so T₁ = 0.40 s.
Same paramagnetic contribution (2.0 s⁻¹) with r₁ = 20: [Gd] = 2.0/20 = 0.10 mM, a fivefold lower dose. Slower tumbling of the protein-bound agent lengthens the rotational correlation time and raises relaxivity.
Practice Q7. Log K values with EDTA (practice values close to literature): Pb²⁺ 18.0, Ca²⁺ 10.7, Zn²⁺ 16.5. Calculate the equilibrium constant for [Ca(EDTA)]²⁻ + Pb²⁺ ⇌ [Pb(EDTA)]²⁻ + Ca²⁺, and comment on whether CaNa₂EDTA might also remove zinc.
Answer
K = K(Pb)/K(Ca) = 10^(18.0 − 10.7) = 10^7.3 ≈ 2.0 × 10⁷: lead displaces calcium essentially completely.
For zinc, K = 10^(16.5 − 10.7) = 10^5.8 ≈ 6 × 10⁵, also highly favourable. So CaNa₂EDTA also mobilises Zn²⁺, and zinc loss is a known side effect of prolonged treatment. EDTA’s selectivity among these metals comes from its total stability constants, not from HSAB softness: it is a hard N₂O₄ donor, which is one reason thiol chelators (DMSA) are preferred for oral lead treatment.
Practice Q8. Consider the statements:
- Carboplatin and cisplatin form the same principal DNA adduct because they share the same carrier ligands.
- The sestamibi complex contains Tc(I) with six isonitrile ligands and is a cation.
- Desferrioxamine binds Fe(III) through six sulfur donors.
- Lead poisoning raises δ-aminolevulinic acid levels because lead inhibits ALA dehydratase.
Which are correct?
(a) 1, 2 and 4 only (b) 2 and 3 only (c) 1 and 4 only (d) 1, 2, 3 and 4
Answer: (a)
- Correct. After the leaving group is lost, both give cis-{Pt(NH₃)₂}²⁺ bound to the same GpG site. 2. Correct: [Tc(CNR)₆]⁺, Tc(I), low-spin \( d^6 \). 3. Wrong: six hydroxamate O donors (hard donors for hard Fe(III)). 4. Correct.
Practice Q9. A sample contains 180 mg of cisplatin (M = 300.05 g mol⁻¹). How many millimoles of Pt, and what mass of platinum, does it contain? (Pt = 195.08)
Answer
n = 180/300.05 = 0.600 mmol. Mass of Pt = 0.600 × 195.08 ≈ 117 mg (platinum is 65.0% of cisplatin by mass).
Quick Revision Table
| Idea | Fact |
|---|---|
| Cisplatin | cis-[PtCl₂(NH₃)₂], from [PtCl₄]²⁻ (trans effect); aquation inside cells; N7-G; 1,2-d(GpG) crosslink; HMG proteins |
| Transplatin | inactive: no 1,2-intrastrand crosslink |
| Carboplatin / oxaliplatin | CBDCA leaving group, slower / oxalate + DACH, active in some resistant tumours |
| SAR | neutral, cis, moderately labile leaving groups, N–H carriers |
| Gd MRI | \( f^7 \), S = 7/2; [Gd(DTPA)(H₂O)]²⁻, [Gd(DOTA)(H₂O)]⁻; q = 1; \( 1/T_1 = 1/T_{1,0} + r_1[\text{Gd}] \); macrocycles more inert |
| ⁹⁹ᵐTc | 140 keV γ, t½ 6 h; ⁹⁹Mo generator (t½ 66 h); TcO₄⁻ + Sn(II) kits; sestamibi Tc(I) |
| Chelators | BAL/DMSA/DMPS (As, Hg, Pb); CaNa₂EDTA (Pb); penicillamine (Cu); desferrioxamine, deferiprone, deferasirox (Fe); Prussian blue (Tl, Cs) |
| Other drugs | Li₂CO₃, auranofin (Au(I)), Bi salts, nitroprusside, Ag sulfadiazine, As₂O₃, Sb(V) |
| Toxic metals | Pb (ALA dehydratase, ferrochelatase), Hg (thiols, MeHg), Cd (replaces Zn), As (thiols, phosphate mimic) |
Key Takeaways
What’s Next
- Bioinorganic Chemistry: Quick Revision: every table from the chapter on one page.
- Revisit the trans effect and Pt(II) substitution behind cisplatin synthesis and activation.
- Back to the chapter overview or the Chemical Sciences syllabus.